Name: Physostigmine Salicylate
Therapy Type: Small Molecule
Target Type: Cholinergic System
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Forest Laboratories, Inc.
Physostigmine salicylate is a reversible acetylcholinesterase inhibitor that effectively increases the concentration of acetylcholine and thus the stimulation of both nicotinic and muscarinic receptors due to the increase in available acetylcholine at the synapse.
No Available References
No Available Further Reading